

I hereby certify that this correspondence is being transmitted via the Office electronic filing system to the U.S. Patent and Trademark Office, on the date shown below.

Dated: July 7, 2008 Signature: /Mark D. Russett/
Mark D. Russett, Reg. No. 41,281

Docket No.: 62936(46342)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Takafumi Ishii et al.

Application No.: 10/525,105

Confirmation No.: 2820

Filed or 371(c) date: February 18, 2005

Art Unit: 1642

For: PREVENTIVES/REMEDIES FOR
CANCER

Examiner: L. Yao

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

Certain of the references were cited in a Supplementary Partial European Search Report issued February 24, 2006 during the prosecution of EPO Patent Application No. 03792750, which corresponds to the above-referenced application. A copy of the Supplementary Partial European Search Report issued February 24, 2006 is enclosed. The documents cited in the Supplementary Partial European Search Report are cited on the enclosed PTO Form SB/08, and copies of the references are enclosed, except for those references which were cited, and for which copies were provided, with the Information Disclosure Statement dated March 6, 2006.

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any document herein be construed *per se* as a representation that such document is prior art. Moreover, Applicant(s) understand(s) the Examiner will make an independent evaluation of the cited documents.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

Please charge our Deposit Account No. 04-1105 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 62936 (46342).

Dated: July 7, 2008

Respectfully submitted,

By: /Mark D. Russett/
Mark D. Russett, Registration No.: 41,281
EDWARDS ANGELL PALMER & DODGE LLP
P.O. Box 55874
Boston, Massachusetts 02205
(617) 239-0100
Attorneys/Agents For Applicants